Full history for every metric is available with a Kvantra account
Amniotics AB (publ) (AMNI.ST)
Key financial summary
Financials in SEK| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | SEK m | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating profit | SEK m | -29 | -31 | |||||
| Net profit | SEK m | -7 | -10 | -31 | -54 | -49 | -31 | -31 |
| EPS reported | SEK | -0.01 | -0.37 | |||||
| Operating cashflow per share | SEK | -0.01 | -0.01 | |||||
| Capex per share | SEK | 0.00 | 0.00 | |||||
| FCF per share | SEK | -0.01 | -0.01 | |||||
| Free cash flow | SEK m | -32 | -29 | |||||
| Net debt | SEK m | -6 | -6 | |||||
| Book value equity | SEK m | 16 | 16 | |||||
| Book value per share | SEK | 0.01 | 0.01 | |||||
| Number of shares | m | 2,806.36 | 1,459.53 | |||||
| DPS (TTM paid) | SEK | 0.00 | 0.00 |
Financial summary
Financials in SEK| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.63 | 0.95 | |||||
| P/S LTM | x | 0.00 | 0.00 | |||||
| P/FCF LTM | x | -0.80 | -0.51 | |||||
| EV/EBITDA LTM | x | -0.72 | -0.34 | |||||
| EV/Sales LTM | x | 0.00 | 0.00 | |||||
| Earnings Yield LTM | % | -122.22% | -203.70% | |||||
| FCF Yield | % | -125.73% | -197.79% | |||||
| Quality | ||||||||
| ROE | % | -198.66% | -362.71% | |||||
| ROIC | % | -160.46% | -160.46% | |||||
| Operating margin | % | 0.00% | 0.00% | |||||
| Gross margin | % | 0.00% | 0.00% | |||||
| FCF/Sales | % | - | - | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | - | - | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -12.31 | -11.31 | |||||
| Net Debt/EBITDA | x | 0.21 | 0.21 | |||||
| EBIT/Net interest | x | -16.18 | -16.18 | |||||
| Net debt/market cap | % | -22.30% | -38.16% | |||||
| Net debt/Equity | x | -0.36 | -0.36 | |||||
| Gross debt/equity | x | 0.17 | 0.17 | |||||
Company overview
Amniotics AB (publ) specializes in the creation, manufacturing, and commercialization of stem cell-based therapies, utilizing mesenchymal stem cells to address critical, life-threatening illnesses. The company's primary therapeutic candidate, PulmoStem, is designed for the treatment of inflammatory and fibrotic conditions affecting the lungs. Furthermore, Amniotics is advancing other promising treatments such as CogniStem for neurological disorders, NephroStem for kidney-specific ailments, and CutiStem for various dermatological issues. Beyond its own pipeline, the firm provides contract development and manufacturing services for advanced therapy medicinal products to pharmaceutical companies, universities, and hospitals. Established in 2015, Amniotics AB is headquartered in Lund, Sweden.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Amniotics AB (publ) (AMNI.ST)
Amniotics AB (publ) specializes in the creation, manufacturing, and commercialization of stem cell-based therapies, utilizing mesenchymal stem cells to address critical, life-threatening illnesses. The company's primary therapeutic candidate, PulmoStem, is designed for the treatment of inflammatory and fibrotic conditions affecting the lungs. Furthermore, Amniotics is advancing other promising treatments such as CogniStem for neurological disorders, NephroStem for kidney-specific ailments, and CutiStem for various dermatological issues. Beyond its own pipeline, the firm provides contract development and manufacturing services for advanced therapy medicinal products to pharmaceutical companies, universities, and hospitals. Established in 2015, Amniotics AB is headquartered in Lund, Sweden.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free